罗替戈汀透皮系统在帕金森病和不宁腿综合征治疗中的关键评价-患者的考虑。

Degenerative Neurological and Neuromuscular Disease Pub Date : 2015-07-03 eCollection Date: 2015-01-01 DOI:10.2147/DNND.S37268
Tigran Kesayan, Jessica D Shaw, Tracy M Jones, Joseph S Staffetti, Theresa A Zesiewicz
{"title":"罗替戈汀透皮系统在帕金森病和不宁腿综合征治疗中的关键评价-患者的考虑。","authors":"Tigran Kesayan,&nbsp;Jessica D Shaw,&nbsp;Tracy M Jones,&nbsp;Joseph S Staffetti,&nbsp;Theresa A Zesiewicz","doi":"10.2147/DNND.S37268","DOIUrl":null,"url":null,"abstract":"<p><p>Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson's disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson's disease and RLS.</p>","PeriodicalId":11147,"journal":{"name":"Degenerative Neurological and Neuromuscular Disease","volume":"5 ","pages":"63-72"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DNND.S37268","citationCount":"2","resultStr":"{\"title\":\"Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations.\",\"authors\":\"Tigran Kesayan,&nbsp;Jessica D Shaw,&nbsp;Tracy M Jones,&nbsp;Joseph S Staffetti,&nbsp;Theresa A Zesiewicz\",\"doi\":\"10.2147/DNND.S37268\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson's disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson's disease and RLS.</p>\",\"PeriodicalId\":11147,\"journal\":{\"name\":\"Degenerative Neurological and Neuromuscular Disease\",\"volume\":\"5 \",\"pages\":\"63-72\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/DNND.S37268\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Degenerative Neurological and Neuromuscular Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/DNND.S37268\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2015/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Degenerative Neurological and Neuromuscular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/DNND.S37268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2015/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

罗替戈汀(RTG)是一种多巴胺激动剂,用于治疗帕金森病和中度至重度不宁腿综合征的单一和辅助治疗。RTG是目前唯一可用的24小时/天透皮系统的多巴胺激动剂,每天给药一次。作为一种透皮贴剂,RTG绕过胃肠道,使其成为吞咽困难患者的治疗选择。RTG的使用也避免了在用餐前后安排给药的需要。这篇综述提供了RTG作为治疗帕金森病和RLS的关键评价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations.

Critical appraisal of rotigotine transdermal system in management of Parkinson's disease and restless legs syndrome - patient considerations.

Rotigotine (RTG) is a dopamine agonist that is used as mono and adjunct therapy to treat Parkinson's disease, and as therapy for moderate-to-severe restless legs syndrome. RTG is the only dopamine agonist currently available as a 24-hour/day transdermal system, providing once-a-day dosing. As a transdermal patch, RTG bypasses the gastrointestinal tract, making it a treatment option for patients with dysphagia. The use of RTG also avoids the need to schedule administration of medication around meals. This review provides a critical appraisal of RTG as treatment of Parkinson's disease and RLS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信